Table 1.

Patient characteristics from patients included in the PBMC study for TCR V-beta CDR3 sequencing

Patient study identificationSex (M/F)EthnicityAgeActive metastasis siteLDHStageMutational statusToxicitiesResponse at EOSPFS (mo)OS (mo)
GA5MC65Skin, LN, adrenalNM1cBRAF V600EPR (but PD after EOS)720
GA7MC62SkinNIIIcBRAF_V600EG2 pruritusPD267
GA8FC48SCHighM1cBRAF_V600EG2 diarrheaPD13
GA9MC52LN, boneHighM1cBRAF_V600EPD314
GA11MC47LNHighM1cNRAS_Q61RPD27
GA12MC76SkinHighM1cBRAF_V600EG3 colitisOff due to AE/PD220
GA13MC37LNNM1aBRAF_V600EG2 hypophysitisPD313
GA14MC38SC, muscleHighM1cHRAS_G12D BRAF_V600E PTEN_N323fsG1 diarrheaPD315
GA15MC58Brain, bowel, liverNM1cNRAS_Q61RG3 rashPD415
GA18FC49SkinNM1aNRAS_Q61RG1 diarrheaCR62+62+
GA19MC55LN, brainNM1cNRAS_Q61R TP53_R175H CTNNB1_S37FG3 diarrhea G2 rashPD336
GA21MC71Skin, SC, LN, liver, spleenHighM1cKIT_L576PPD38
GA23MC27LungNM1bPD24
GA24MC81SC, lungHighM1cG1 nauseaPD23
GA25MH71LNHighM1cKIT_N822KPD38
GA26MC68LN, lungNM1bBRAF_V600EG3 diarrhea G1 Grover'sPD151
GA27MC52Axillary, clavicularHighM1cBRAF_V600E CDKN2A_E61b PIK3CA_3545KG2 pruritus G1 diarrhea G1 hypophysitisPD611
GA28MC48LN, LungHighM1cBRAF_G466E EGFR_P753S ABL1_E255KPD24
GA29FC79Skin, SCNIIIcBRAF_V600E KIT_V559AG3 diarrhea G1 pruritusCR4545
GA32MC36MuscleNM1cPD556
GA33FC49SkinNIIIcBRAF_V600EG2 adrenal insufficiencyCR55+55+

Abbreviations: AE, adverse effects; C, Caucasian; EOS, end of study; H, Hispanic; LN, lymph nodes; N, normal; Neg, negative; OS, overall survival; PD, progressive disease; PFS, progression-free survival; SC, subcutaneous.